For example, Elihu Estey et al. [18] doubted whether it was warranted for FDA to approve ivosidenib for IDH1-mutated newly diagnosed elderly AML based on CR + CRh without survival or event-free survival data [17]. Here, IDH1 is linked to acute myeloid leukemia.